Get the Stockscreener App
464.56
0.54%
-2.51
After Hours:
464.56
Vertex Pharmaceuticals Inc stock is traded at $464.56, with a volume of 920.94K.
It is down -0.54% in the last 24 hours and down -2.75% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$467.07
Open:
$464.81
24h Volume:
920.94K
Relative Volume:
0.85
Market Cap:
$119.70B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
34.85
EPS:
13.33
Net Cash Flow:
$-1.35B
1W Performance:
+2.95%
1M Performance:
-2.75%
6M Performance:
+1.67%
1Y Performance:
+32.66%
1-Day Range:
$462.01
$470.42
1-Week Range:
$445.00
$470.42
52-Week Range:
$346.29
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
MetLife Investment Management LLC Sells 1,828 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
VRTX (Vertex Pharmaceuticals) Inventory-to-Revenue : 0.36 (As of Sep. 2024) - GuruFocus.com
Fmr LLC Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Dai ichi Life Insurance Company Ltd Lowers Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Bank of Montreal Can - MarketBeat
The Manufacturers Life Insurance Company Sells 11,350 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
JPMorgan's 2025 Biotech Outlook: Vertex (VRTX) Leads the Pack - GuruFocus.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex leads J.P. Morgan's top biotech picks list for 2025 (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharma: Why I Am Buying This Dip (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Eagle Asset Management Inc. - MarketBeat
Loomis Sayles & Co. L P Has $1.43 Billion Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders are still up 137% over 3 years despite pulling back 3.4% in the past week - Yahoo Finance
Daiwa Securities Group Inc. Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Pacer Advisors Inc. Sells 5,885 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
VRTX (Vertex Pharmaceuticals) Cash Flow from Investing : $-3,835 Mil (TTM As of Sep. 2024) - GuruFocus.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Icon Wealth Advisors LLC - MarketBeat
Edgewood Management LLC Has $719.19 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
What is Zacks Research's Estimate for VRTX FY2024 Earnings? - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Intech Investment Management LLC Has $8.24 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock - Insider Monkey
Got $500? 1 Biotech Stock to Buy and Hold Forever - Yahoo! Voices
MAI Capital Management Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BofA flags Vertex Pharma stock at risk of double top breakdown - Investing.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
January 2025 Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Citizens Financial Group Inc. RI - MarketBeat
Massachusetts Financial Services Co. MA Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Integrated Investment Consultants LLC Invests $9.18 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
PNC Financial Services Group Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded to "Buy" Rating by StockNews.com - MarketBeat
Advisors Asset Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Portfolio Design Labs LLC - MarketBeat
EULAV Asset Management Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jennison Associates LLC - MarketBeat
MWA Asset Management Sells 2,018 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
57,825 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Segall Bryant & Hamill LLC - MarketBeat
Northwest Bancshares Inc. Sells 2,683 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - MSN
Strategy Asset Managers LLC Has $1.26 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Prospera Financial Services Inc - MarketBeat
Pathstone Holdings LLC Purchases 2,112 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Quest Partners LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
B. Metzler seel. Sohn & Co. Holding AG Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):